Skip to content

Author

T. Heffernan

We have 3 of 202 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Abstract A027: Leveraging genomic copy-number complexity in uveal melanoma to drive novel therapeutic development

It is demonstrated that uveal melanoma progression reflects an integrated CN-transcriptional ecosystem extending beyond chromosome 3 loss, with cytoband-level genomic evolution shaping malignant fitness and therapeutic response.

Johnathon L. Rose, Sanjana Srinivasan, A. Cooper et al. · 0 citations
Open access Jul 2026

Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer

It is shown that KRAS targeting with MRTX1133 or Daraxonrasib specifically synergizes with anti-CTLA4, but not other immune checkpoint inhibitors, in inducing tertiary lymphoid structures and promoting anti-tumor immune responses in preclinical pancreatic cancer models.

Krishnan K. Mahadevan, A. S. Maldonado, Bing-Rui Li et al. · 0 citations
Open access Jul 2026

CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC

Mediator complex kinase CDK8 is identified as a driver of resistance towards KRASG12D inhibition in pancreatic ductal adenocarcinoma (PDAC), promoting stromal remodeling and immunosuppression and CDK8 inhibition in resistant tumors re-primes PDAC to anti-CTLA-4 immunotherapy efficacy.

Kathleen M. McAndrews, Krishnan K. Mahadevan, Bingrui Li et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.